Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders
The present application provides methods of treating PI3Kδ related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.
1. A method of treating chronic lymphocytic leukemia (CLL), hairy cell leukemia, Mantle cell lymphoma, small lymphocytic lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, activated B-cell like (ABC) diffuse large B cell lymphoma, or germinal center B cell (GCB) diffuse large B cell lymphoma in a patient, comprising administering to said patient a therapeutically effective amount of a compound of a compound, which is a 4-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is (S)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the compound is (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the compound is (S)-4-(3-((R)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the compound is (R)-4-(3-((R)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 , which is a method of treating chronic lymphocytic leukemia (CLL).
7. The method of claim 1 , which is a method of treating hairy cell leukemia.
8. The method of claim 1 , which is a method of treating Mantle cell lymphoma.
9. The method of claim 1 , which is a method of treating small lymphocytic lymphoma.
10. The method of claim 1 , which is a method of treating follicular lymphoma.
11. The method of claim 1 , which is a method of treating lymphoplasmacytic lymphoma.
12. The method of claim 1 , which is a method of treating extranodal marginal zone lymphoma.
13. The method of claim 1 , which is a method of treating activated B-cell like (ABC) diffuse large B cell lymphoma.
14. The method of claim 1 , which is a method of treating germinal center B cell (GCB) diffuse large B cell lymphoma.
15. The method of claim 2 , which is a method of treating chronic lymphocytic leukemia (CLL).
16. The method of claim 2 , which is a method of treating hairy cell leukemia.
17. The method of claim 2 , which is a method of treating Mantle cell lymphoma.
18. The method of claim 2 , which is a method of treating small lymphocytic lymphoma.
19. The method of claim 2 , which is a method of treating follicular lymphoma.
20. The method of claim 2 , which is a method of treating lymphoplasmacytic lymphoma.
21. The method of claim 2 , which is a method of treating extranodal marginal zone lymphoma.
22. The method of claim 2 , which is a method of treating activated B-cell like (ABC) diffuse large B cell lymphoma.
23. The method of claim 2 , which is a method of treating germinal center B cell (GCB) diffuse large B cell lymphoma.
24. The method of claim 3 , which is a method of treating chronic lymphocytic leukemia (CLL).
25. The method of claim 3 , which is a method of treating hairy cell leukemia.
26. The method of claim 3 , which is a method of treating Mantle cell lymphoma.
27. The method of claim 3 , which is a method of treating small lymphocytic lymphoma.
28. The method of claim 3 , which is a method of treating follicular lymphoma.
29. The method of claim 3 , which is a method of treating lymphoplasmacytic lymphoma.
30. The method of claim 3 , which is a method of treating extranodal marginal zone lymphoma.
31. The method of claim 3 , which is a method of treating activated B-cell like (ABC) diffuse large B cell lymphoma.
32. The method of claim 3 , which is a method of treating germinal center B cell (GCB) diffuse large B cell lymphoma.
33. The method of claim 4 , which is a method of treating chronic lymphocytic leukemia (CLL).
34. The method of claim 4 , which is a method of treating hairy cell leukemia.
35. The method of claim 4 , which is a method of treating Mantle cell lymphoma.
36. The method of claim 4 , which is a method of treating small lymphocytic lymphoma.
37. The method of claim 4 , which is a method of treating follicular lymphoma.
38. The method of claim 4 , which is a method of treating lymphoplasmacytic lymphoma.
39. The method of claim 4 , which is a method of treating extranodal marginal zone lymphoma.
40. The method of claim 4 , which is a method of treating activated B-cell like (ABC) diffuse large B cell lymphoma.
41. The method of claim 4 , which is a method of treating germinal center B cell (GCB) diffuse large B cell lymphoma.
42. The method of claim 5 , which is a method of treating chronic lymphocytic leukemia (CLL).
43. The method of claim 5 , which is a method of treating hairy cell leukemia.
44. The method of claim 5 , which is a method of treating Mantle cell lymphoma.
45. The method of claim 5 , which is a method of treating small lymphocytic lymphoma.
46. The method of claim 5 , which is a method of treating follicular lymphoma.
47. The method of claim 5 , which is a method of treating lymphoplasmacytic lymphoma.
48. The method of claim 5 , which is a method of treating extranodal marginal zone lymphoma.
49. The method of claim 5 , which is a method of treating activated B-cell like (ABC) diffuse large B cell lymphoma.
50. The method of claim 5 , which is a method of treating germinal center B cell (GCB) diffuse large B cell lymphoma.